• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biontech Se ADR (NQ: BNTX )

    85.39 -0.07 (-0.08%)
    Streaming Delayed Price Updated: 2:55 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 241,687
    Open 86.72
    Bid (Size) 85.26 (4)
    Ask (Size) 85.49 (4)
    Prev. Close 85.46
    Today's Range 84.42 - 86.80
    52wk Range 78.02 - 125.83
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
    From BioNTech SE
    Via GlobeNewswire
    European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
    European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
    Via Benzinga
    Exposures COVID-19

    Performance

    YTD
    -23.99%
    -23.99%
    1 Month
    +0.89%
    +0.89%
    3 Month
    -2.98%
    -2.98%
    6 Month
    -14.45%
    -14.45%
    1 Year
    -20.22%
    -20.22%

    More News

    Read More
    GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
    Via Benzinga
    Exposures COVID-19
    Evaluating BioNTech: Insights From 12 Financial Analysts
    Via Benzinga
    Evaluating BioNTech: Insights From 15 Financial Analysts
    Via Benzinga
    London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
    Via MarketBeat
    Topics ETFs
    Exposures COVID-19
    3 Nasdaq Stocks to Sell in July Before They Crash & Burn
    Via InvestorPlace
    Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
    Via InvestorPlace
    AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
    Via Benzinga
    Exposures Product Safety
    Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
    From Pfizer Inc.
    Via Business Wire
    Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
    From BioNTech SE
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
    From BioNTech SE
    Via GlobeNewswire
    GameStop And First Solar Were Among The 10 Biggest Large Cap Losers Last Week (June 16-June 22): Are These In Your Portfolio?
    Via Benzinga
    Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
    Via Benzinga
    Exposures COVID-19
    Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
    Via Benzinga
    Exposures Product Safety
    Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
    Via Benzinga
    Exposures COVID-19 Product Safety
    Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
    Via AB Newswire
    Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
    Via AB Newswire
    What's Going On With Novavax Stock?
    Via Benzinga
    Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
    Via Talk Markets
    Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
    From Genmab A/S
    Via Business Wire
    Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
    From BioNTech SE
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.